drug

Trial of a new drug in KRAS-mutant lung cancer

A new study has just been launched that will study a new drug, VIC-1911, alone or given in combination with Lumakras (sotorasib) for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to VITRAC Therapeutics, the maker of VIC-1911. VIC-1911 works by inhibiting the amplification or overexpression of the AURKA gene, which previous research …

Trial of a new drug in KRAS-mutant lung cancer Read More »

Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

TORONTO, December 28, 2022—(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or “Society“) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotechnology company focused on developing the next generation of medicines to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the healing power of psychedelic molecules, is pleased to announce that successfully completed the …

Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease Read More »

PeptiDream announces a new research and collaboration agreement with Lilly for the discovery of novel peptide drug conjugates

KANAGAWA, Japan–(BUSINESS WIRE)–PeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kanagawa, Japan (Chairman: Patrick C. Reid, “PeptiDream”) (Tokyo: 4587) today announced that it has entered into a Research Collaboration and License Agreement with the US – based at Eli Lilly and Company (Lilly) focused on the discovery and development of new peptide drug conjugates …

PeptiDream announces a new research and collaboration agreement with Lilly for the discovery of novel peptide drug conjugates Read More »

BioNxt Solutions signs terms for new precision drug coating platform technology

VANCOUVER, BC / ACCESSWIRE / December 12, 2022 / BioNxt Solutions Inc. (“BioNxt” or “Society“) (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) is pleased to announce that it has signed a non-binding term sheet (“Term Sheet”) to acquire certain intellectual property assets and rights related to new technology to deliver coatings for solid oral dosage form of the drug (“Technology”). The …

BioNxt Solutions signs terms for new precision drug coating platform technology Read More »